OncoMatch/Clinical Trials/NCT06727617
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Is NCT06727617 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Serplulimab and Chemotherapy for cervical cancers.
Treatment: Serplulimab · Chemotherapy — A Phase II Study of Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer with Multiple Risk Factors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) cps ≥1 (cps ≥1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgery
Have undergone radical hysterectomy (Piver classification) and pelvic lymphadenectomy of type II or III
Cannot have received: pelvic radiotherapy
Patients who have previously received pelvic radiotherapy
Lab requirements
Blood counts
absolute neutrophil count of at least 1.5 × 10⁹/l; platelet count of at least 100 × 10⁹/l
Kidney function
creatinine levels not exceeding the upper limit of normal
Liver function
total bilirubin, alt, and ast levels not exceeding 1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06727617 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 cps ≥1 is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages